News | Left Atrial Appendage (LAA) Occluders | August 21, 2020

COVID-19 Boosts Demand for Left Atrial Appendage Closure Devices Market

COVID-19 worldwide increased demand for LAA occluder devices to reduce clinic visits and hospitalizations in high risk bleeding patients

Boston Scientific recently introduced the newst iteration of LAA occluder device, the Watchman FLX. It uses small spikes to help better anchor the device and prevent embolization.

Boston Scientific recently introduced the newst iteration of LAA occluder device, the Watchman FLX. It uses small spikes to help better anchor the device and prevent embolization. Read more on this FDA approval.

August 21, 2020 — According to a report published by Research Dive, the rising number of patients suffering from atrial fibrillation (AF) and the growing geriatric population are the major factors expected to propel the growth of the global left atrial appendage closure devices market. In addition, the rising cases of COVID-19 is resulting in increasing demand for left atrial appendage (LAA) closure devices to ween patients off of anticoagulation and eliminate the need for regular Coumadin clinic visits for INR testing used to maintain the drug at therapeutic levels. This is helping the market to witness a progressive growth in the pandemic crisis. 

Conversely, the availability of alternative technology and the high costs associated with the LAA closure devices is likely to hamper the market growth in the near future. The report includes detailed analysis on drivers, restraints, challenges, major segments, growth opportunities and strategic growth by market players to better apprehend the effect of COVID-19 pandemic on the global market.

COVID-19 Impact on Left Atrial Appendage Closure Devices Market Report Highlights:

   • The CAGR of the left atrial appendage closure devices market as estimated before the outbreak of COVID-19 pandemic was 23.1% over the forecast period.
   • The CAGR of the global industry, as projected post the onset of COVID-19 crisis, is expected to grow at 24% during the forecast period.
   • The market size of the left atrial appendage closure devices industry in 2020, as estimated before the COVID-19 pandemic began was $572.9 million.
   • The real-time market size in 2020, bearing the after-effects of the COVID-19 pandemic is $585.2 million

Download a sample analysis report on the LAA closure devices market.

Current LAA Closure Market Transformation During COVID-19 Crisis

The LAA closure devices industry is likely to experience a surge in the growth rate during the coronavirus pandemic. The governments of various countries are taking initiatives to create awareness amongst people regarding the importance of left atrial appendage closure devices during the pandemic, which is the major factor expected to boost the market growth in 2020. Besides, a number of manufacturers are stressing their activities on product improvements to obtain a strong position and sustain in the global market in coronavirus emergency. 

For instance, in February 2020, Abbott received the U.S. Food and Drug Administration (FDA) approval for its newly innovated Amplatzer Amulet Left Atrial Appendage Occluder, which is designed for AF patients. This is expected to create lucrative opportunities in the market in the trying times.

Post-Pandemic LAA Closure Market Landscape

As per the report, the global LAA closure devices market is anticipated to witness a tremendous growth even after the COVID-19 pandemic. The continuous advancements in technology, government support for medical device approvals, rise in number of ambulatory clinical centers globally, and developments by prominent market players are the major factors expected to bolster the market growth.

The key players operating in the global industry include:
   • Boston Scientific Corp.
   • SentreHEART Inc.
   • AtriCure Inc.
   • Occlutech
   • Abbott
   • Lifetech Scientific
   • Aegis Medical Group.
   • Cardia Inc.
   • Johnson & Johnson Services Inc.
   • Biosense Webster Inc.

The report also summarizes other important aspects of the key players including Financial Performance, Product Portfolio, SWOT analysis, and Recent Strategic moves and developments. 

Read more about the thee most commonly used LAA closure devices across the globe are the Watchman, Lariat and the Amplatzer.  

Research Dive is a market research firm based in Pune, India. Scrutinizing relevant news releases, government publications, decades of trade data, and technical and white papers, Research Dive delivers the required services to its clients well within the required timeframe. 

Get Sample Report [75 pages]

For more information: www.researchdive.com

 

Related LAA Occlusion Device Content:

AtriCure Receives Clearance for Expanded Labeling Claims for AtriClip Devices

Conformal Medical Secures $85 Million in Funding for Left Atrial Appendage Occluder Trial

VIDEO: Overview of LAA Occlusion Using the Watchman FLX

FDA Clears Next-generation Watchman FLX Left Atrial Appendage Occluder

Amplatzer Amulet LAA Occluder Will be Compared to Anticoagulants in CATALYST Trial

First-Of-Its-Kind, No-Implant LAA Occluder Noted for Innovation at 2019 ICI Meeting

Find more LAA occluder news and video

Related Content

The TactiFlex PAF investigational device exemption (IDE) study will evaluate he investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) to treat people suffering from paroxysmal atrial fibrillation (PAF). 

The TactiFlex PAF investigational device exemption (IDE) study will evaluate he investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) to treat people suffering from paroxysmal atrial fibrillation (PAF). 

News | Atrial Fibrillation | August 04, 2020
August 4, 2020 — Abbott announced the first enrollments in the TactiFlex PAF  investigational device exemption (IDE)
PREDICT-AF trial showed first time there is extensive extracellular matrix remodeling. #HRS2020 #Heartrhythm2020. Marilyn Fornell
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Structural changes of the atrium may occur long before the onset of atrial fibrillation (AF), and the
Results of the Atrial Fibrosis Predicts Recurrent Stroke Or New Atrial Fibrillation In Patients With Embolic Stroke Of Undetermined Source - A Multi-Center Study at HRS 2020. #HRS2020 #Heartrhythm2020,
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Atrial disease has been implicated in embolic stroke of undetermined source (ESUS) and a late-breaking
Contact Force Sensing Catheter Improved Outcomes in Persistent Atrial Fibrillation Ablation. #HRS2020 #heartrhythm2020
News | Atrial Fibrillation | May 13, 2020
May 13, 2020 — The PRECEPT study testing the use of the Biosense Webster Thermocool Smarttouch SF Catheter for the tr
The Swiss-AF study shows High Incidence Of Silent Brain Infarcts Found in Anticoagulated Atrial Fibrillation Patients. #Heartrhythm2020 #HRS20 #HRS2020
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 – A new clinical study found that patients with...
PINNACLE FLX Study of New Watchman FLX LAA Occluder Meets Safety and Efficacy Endpoints. #Heartrhythm2020 #HRS20 #HRS2020
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 — Positive 12-month results were announced today from the...
The first-in-human results show positive results for Medtronic's pulsed field ablation in safety and efficiency. #Heartrhythm2020 #HRS2020 #HRS20
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 — New clinical trial reveals the first-in-human results for paroxysmal or persistent atrial fibrillation
POPULAR TAVR trial Shows Oral Anticoagulants Alone in atrial fibrillation  (AF) Patients Reduces Bleeding Post TAVR, transcatheter aortic valve replacement. #ACC20 #ACC2020
News | Atrial Fibrillation | March 29, 2020
March 29, 2020 — Patients with atrial fibrillation (AF) who took oral anticoagulants alone after undergoing transcath
Medtronic's PulseSelect Pulsed Field Ablation (PFA) System

Medtronic's PulseSelect Pulsed Field Ablation (PFA) System.

News | Atrial Fibrillation | January 31, 2020
January 31, 2020 – The U.S.
Frequent Drinking Greater Risk Factor for Heart Rhythm Disorder Than Binge Drinking

Image courtesy of the American Heart Association.

News | Atrial Fibrillation | October 22, 2019
October 22, 2019 —  Drinking small amounts of alcohol frequently is linked with a higher likelihood of...